(Q34442510)

English

Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

phase II clinical trial

0 references

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

5

object named as

Jes Olesen

0 references

Richard B. Lipton

4

object named as

Richard B Lipton

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

6

object named as

Messoud Ashina

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Peter J. Goadsby

2

object named as

Peter J Goadsby

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

object named as

David W Dodick

1

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Stephen D. Silberstein

3

object named as

Stephen D Silberstein

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

author name string

Kerri Wilks

7

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

David Kudrow

8

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Robin Kroll

9

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Bruce Kohrman

10

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Robert Bargar

11

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Joe Hirman

12

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Jeff Smith

13

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

ALD403 study investigators

14

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

publication date

5 October 2014

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Lancet Neurology

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

13

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

1100-1107

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970209-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The use of migraine preventive medications among patients with and without migraine headaches

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970209-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Patterns of medication use by chronic and episodic headache sufferers in the general population: results from the frequent headache epidemiology study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970209-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Tolerance and loss of beneficial effect during migraine prophylaxis: clinical considerations

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970209-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Adherence with migraine prophylaxis in clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970209-1

7 January 2021

based on heuristic

inferred from DOI database lookup

CGRP and its receptors provide new insights into migraine pathophysiology

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970209-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970209-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970209-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970209-1

7 January 2021

based on heuristic

inferred from DOI database lookup

BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970209-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970209-1

7 January 2021

based on heuristic

inferred from DOI database lookup

mRNA expression of 5-hydroxytryptamine 1B, 1D, and 1F receptors and their role in controlling the release of calcitonin gene-related peptide in the rat trigeminovascular system

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970209-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970209-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapeutic prospects for migraine: can paradise be regained?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970209-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970209-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Placebo response in the prophylaxis of migraine: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970209-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Factors associated with the prophylactic effect of placebo injections in subjects enrolled in a study of botulinum toxin for migraine.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970209-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The importance of placebo in headache research

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970209-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Calcitonin gene-related peptide (CGRP) and its receptor components in human and rat spinal trigeminal nucleus and spinal cord at C1-level

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970209-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Possible sites of action of the new calcitonin gene-related peptide receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970209-1

7 January 2021

based on heuristic

inferred from DOI database lookup

New drugs in migraine treatment and prophylaxis: telcagepant and topiramate

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970209-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Pearls and pitfalls in neural CGRP immunohistochemistry

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970209-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Calcitonin gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970209-1

7 January 2021

based on heuristic

inferred from DOI database lookup

CGRP-receptor antagonism in migraine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970209-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970209-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Methods to explain the clinical significance of health status measures

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970209-1

7 January 2021

based on heuristic

inferred from DOI database lookup

What is a clinically relevant change on the HIT-6 questionnaire? An estimation in a primary-care population of migraine patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970209-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Minimal important differences in the Migraine-Specific Quality of Life Questionnaire (MSQ) version

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970209-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1474-4422(14)70209-1

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34442510&oldid=1550963159"